Saturday 17 October 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.83
0.79
−3.83%
Follow NAMS
| Dec '17 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 5 | 3 |
P/E ratio |
— | — | — | — | — | 8.09 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | 10.24 | 3.45 | 7.43 | 13.11 | 27.63 |
P/S ratio |
— | — | — | — | — | 0.00 | 0.00 | 43.24 | 53.22 | 184.61 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 15.05 | 14.38 | 4.25 | 9.69 | 8.19 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 19.92 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | 57.20 | 18.52 | (29.69) | (64.70) | (101.63) |
P/B ratio |
— | — | — | — | — | 0.00 | 0.49 | 3.40 | 3.20 | 6.08 |
Price to Tangible BV |
— | — | — | — | — | 0.00 | 0.49 | 3.41 | 3.20 | 6.08 |
EV/Sales |
— | — | — | — | — | 0.00 | 0.00 | 28.25 | 34.91 | 156.28 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 2.40 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (235.43) | (23.94) | (4.54) | (10.03) | (23.80) |
EV/FCF |
— | — | — | — | — | (235.43) | (23.94) | (4.54) | (9.99) | (23.76) |
Quick Ratio |
— | 5.77 | 5.77 | 0.00 | 5.52 | 0.00 | 12.97 | 6.82 | 7.85 | 7.43 |
Current Ratio |
— | 7.90 | 7.90 | 5.96 | 6.70 | 12.64 | 13.26 | 6.95 | 8.08 | 7.88 |
Net Debt/EBITDA |
— | 10.69 | 10.69 | 1.76 | 0.90 | 94.51 | 131.83 | 1.86 | 4.74 | 2.83 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 | 0.03 | 0.08 | 0.03 |
Operating CF/Net income |
— | (12.05) | (12.05) | 0.88 | (0.03) | (0.10) | (0.47) | 0.80 | 0.66 | 0.73 |
Capex/Depreciation |
— | — | (13.00) | 0.00 | (1.43) | 0.00 | (24.56) | (0.49) | (5.95) | (1.12) |
Interest Coverage |
— | (283.78) | (0.37) | 0.00 | (6.33) | (866.88) | (12.39) | — | — | — |
| — | 0.07% | 0.07% | 0.00% | (49.46%) | 0.00% | (10.68%) | (49.25%) | (46.20%) | (28.29%) | |
| — | 0.06% | 0.03% | 0.00% | 2.99% | 0.00% | (7.32%) | (42.86%) | (39.88%) | (24.95%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (307.51%) |
Return on Tangible Assets |
— | 2.54% | 2.54% | 0.00% | 287.00% | (18.62%) | (5.12%) | (59.59%) | (31.93%) | (34.53%) |
Average Days of Receivables |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 39.66 | 0.00 |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 84.34% | 84.47% | 1,131.47% | 332.30% | 630.28% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 20.49% | 19.00% | 267.09% | 154.61% | 472.62% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | 0.00% | 4.01% | 174.39% | 73.79% | 264.08% |
Graham Net Nets |
— | — | — | — | — | (4.27) | 2.02 | 0.29 | 0.31 | 0.14 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | 12.36% | (10.66%) | (22.40%) | (10.12%) | (4.93%) |
Free Cash Flow Yield |
— | — | — | — | — | (0.41%) | 5.02% | (14.39%) | (6.57%) | (3.56%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 1.26 | 5.41 | 0.17 | 0.48 | 0.19 |
Operating CF per Share |
— | (0.03) | (0.16) | (1.23) | (0.04) | 0.10 | 0.56 | (1.72) | (1.68) | (1.25) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (0.03) | (0.16) | (1.23) | (0.05) | 0.10 | 0.55 | (1.72) | (1.69) | (1.25) |
Cash per Share |
— | 0.08 | 0.44 | 2.50 | 0.36 | 5.74 | 24.66 | 4.14 | 8.84 | 5.38 |
Shareholders Equity per Share |
— | 7.18 | (3.39) | 2.35 | (1.84) | 6.34 | 22.68 | 3.51 | 8.03 | 5.77 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 7.18 | (3.39) | 2.35 | (1.84) | 6.34 | 22.68 | 3.51 | 8.03 | 5.77 |
Free Cash Flow |
— | (0.50) | (0.51) | (29.74) | (0.16) | 8.38 | 10.44 | (141.24) | (159.24) | (148.03) |
Working Capital |
— | 1.63 | 1.63 | 55.72 | 1.27 | 440.42 | 441.92 | 296.89 | 756.50 | 589.91 |
Capital Expenditures |
— | — | (0.01) | (0.02) | (0.02) | (0.01) | (0.22) | (0.02) | (0.67) | (0.25) |
Net Current Asset Value |
— | (10.54) | (148.54) | 55.59 | (144.38) | 428.04 | 429.55 | 288.09 | 756.29 | 589.85 |
EV/EBIT |
— | — | — | — | — | 0.00 | 71.78 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | 0.00 | 0.08 | 0.07 | 0.49 | 0.26 | 1.07 | 0.47 | 0.57 |
Cash ROIC |
— | (0.39%) | 5.59% | (25.42%) | 3.09% | 0.85% | 1.16% | (22.46%) | (10.00%) | (11.21%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 12.98 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | 0.00 | — | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | 0.00 | — | — | — | — |
Average Receivables |
— | — | — | — | — | 3.48 | — | — | 3.51 | — |
Average Payables |
— | 0.16 | 0.16 | 3.62 | 0.16 | 6.01 | 6.01 | 14.39 | 10.83 | 6.86 |
Average Assets |
— | 69.93 | 139.87 | 103.93 | 139.69 | 353.42 | 309.00 | 412.80 | 605.86 | 816.95 |
Average Common Equity |
— | 58.46 | 58.46 | 23.04 | (8.45) | 255.37 | 211.85 | 359.23 | 522.95 | 720.47 |
Columns are period end dates